Skip to main content
Terug
HGYMF logo

Hogy Medical Co.,Ltd.

Datakwaliteit: 100%
Overbought
HGYMF
OTC Healthcare Medical - Instruments & Supplies
€ 34,99
€ 0,00 (0,00%)
Marktkapitalisatie: 754,38M
Dagbereik
€ 34,99 € 35,03
52-Weeksbereik
€ 24,34 € 35,51
Volume
200
50D / 200D Gem.
€ 34,99 / € 30,86
Vorige Slotkoers
€ 34,99

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E 0,5 0,3
P/B 0,0 2,9
ROE % 1,9 3,7
Net Margin % 3,9 3,8
Rev Growth 5Y % 1,8 10,0
D/E 0,2 0,2

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 1,61
€ 1,61 – € 1,61
 43 B 1
FY2029 € 1,08
€ 1,08 – € 1,08
 42 B 1
FY2028 € 0,96
€ 0,96 – € 0,96
 39 B 1

Belangrijkste Punten

Revenue grew 1,76% annually over 5 years — modest growth
Earnings declined -45,79% over the past year
ROE of 1,89% is below average
Debt/Equity of 0,19 — conservative balance sheet
Generating 6,25B in free cash flow
P/E of 0,50 — trading at a low valuation

Groei

Revenue Growth (5Y)
1,76%
Revenue (1Y)0,10%
Earnings (1Y)-45,79%
FCF Growth (3Y)926,74%

Kwaliteit

Return on Equity
1,89%
ROIC3,24%
Net Margin3,88%
Op. Margin9,73%

Veiligheid

Debt / Equity
0,19
Current Ratio4,26
Interest Coverage54,43

Waardering

P/E Ratio
0,50
P/B Ratio0,01
EV/EBITDA-1,96
Dividend Yield0,02%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 0,10% Revenue Growth (3Y) 0,20%
Earnings Growth (1Y) -45,79% Earnings Growth (3Y) -40,66%
Revenue Growth (5Y) 1,76% Earnings Growth (5Y) -25,59%
Profitability
Revenue (TTM) 39,14B Net Income (TTM) 1,52B
ROE 1,89% ROA 1,55%
Gross Margin 32,25% Operating Margin 9,73%
Net Margin 3,88% Free Cash Flow (TTM) 6,25B
ROIC 3,24% FCF Growth (3Y) 926,74%
Safety
Debt / Equity 0,19 Current Ratio 4,26
Interest Coverage 54,43 Dividend Yield 0,02%
Valuation
P/E Ratio 0,50 P/B Ratio 0,01
P/S Ratio 0,02 PEG Ratio -1,30
EV/EBITDA -1,96 Dividend Yield 0,02%
Market Cap 754,38M Enterprise Value -7,46B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 39,14B 39,10B 38,98B 302,13M 36,50B
Net Income 1,52B 2,80B 4,32B 4,37B 4,96B
EPS (Diluted) 67,98 115,54 177,95 153,00 164,03
Gross Profit 12,62B 13,06B 113,44M 120,04M 130,51M
Operating Income 3,81B 4,17B 6,63B 6,14B 5,63B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 97,90B 100,04B 769,11M 813,01M 956,05M
Total Liabilities 23,56B 13,92B 139,24M 155,82M 87,70M
Shareholders' Equity 74,32B 86,11B 83,61B 79,96B 95,88B
Total Debt 13,79B 5,82B 8,89B 10,00B 330,00M
Cash & Equivalents 22,01B 19,42B 138,14M 113,53M 180,19M
Current Assets 44,20B 43,03B 40,29B 35,29B 41,32B
Current Liabilities 10,38B 8,24B 11,13B 9,35B 7,59B

Strategiescores

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#156 of 827
59
Value Defensive Investing (Benjamin Graham)
#340 of 709
29

Recente Activiteit

Ingestapt Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt Defensive Investing (Benjamin Graham)
Mar 24, 2026